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A B S T R A C T
Purpose: The objective of this study was to explore the efﬁcacy of low dose of oxcarbazepine (OXC) in
adult patients with newly diagnosed partial epilepsy in an actual clinical setting. The associated factors
inﬂuencing the poor control of seizures were also evaluated.
Methods: The epilepsy database (2010–2014) from the Epilepsy Clinic of West China Hospital was
retrospectively reviewed.
Results: A total of 102 adult patients with newly diagnosed, previously untreated partial epilepsy
initially treated with OXC were included, and divided into good response group (64) and poor response
group (38) according to whether they were seizure-free for at least 12 months. There were 27 (26.5%)
patients becoming seizure-free with OXC 600 mg/day monotherapy. The remaining 75 patients had
doses of either increasing OXC to 900 mg/day (n = 59) or the addition of another antiepileptic drug (AED)
(n = 16), with another 20 (19.6%) and six (5.9%) patients becoming seizure-free, respectively (P = 0.788).
In addition, two (2.0%) and nine (8.8%) patients became seizure-free with OXC > 900 mg/day
monotherapy and OXC  900 mg/day combination therapy, respectively. Multivariate binary logistic
regression analysis revealed that the time from onset of epilepsy to treatment initiation is signiﬁcantly
associated with seizure control (P = 0.02).
Conclusion: Our results indicated that OXC at low to moderate doses is effective for the treatment of
Chinese adult patients with newly diagnosed, previously untreated partial epilepsy, and a longer time
interval from the onset of epilepsy to the start of treatment signiﬁcantly predicts poor seizure control.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Oxcarbazepine (OXC) is a second generation AED as a ﬁrst-line
treatment for adults and children with simple partial seizures,
complex partial seizures, and partial seizures evolving to
secondarily generalized seizures [1–3]. OXC is chemically related
to carbamazepine (CBZ), but with a more favourable pharmacoki-
netic proﬁle and improved tolerability proﬁle [4,5]. To better
manage and improve the prognosis of epilepsy, it is important to
assess the treatment effects of AED accurately and formulate
rational treatment plans, ideally by following outcomes from the* Corresponding author at: Department of Neurology, West China Hospital,
Sichuan University, No. 37 Guoxue Road, Chengdu, Sichuan 610041, China.
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights repoint of treatment initiation. The efﬁcacy and tolerability of OXC as
monotherapy or adjunctive therapy, has been previously evaluated
in a number of clinical trials [4,6–10]. For adults, this drug has
been shown to be efﬁcacious at a usual maintenance dose of 900–
1200 mg/day and a maximum dose of 2400 mg/day as mono-
therapy or adjunctive therapy [4,7,9–11], but limited data are
available for Chinese patients [12], and since there exists difference
in race between Chinese and Occidentals, a different dose of OXC
treatment in Chinese adult patients may be required. On the other
hand, with strict entry and dosing criteria, regular clinical trials
may fail to include practical, real world information [13,14].
Moreover, the duration of follow-up in trials is usually short, and
may not be long enough to assess drug side effects [15]. Therefore,
rational studies in clinical practice are increasingly recognized to
provide data that further conﬁrm and complement information
derived from regulatory trials [13]. To our knowledge, for patients
who are failure with the initial OXC treatment, whether increasingserved.
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and no data are available.
Therefore, we designed this retrospective study to explore the
efﬁcacy of OXC treatment in adult patients with newly diagnosed,
previously untreated partial epilepsy in west China in an actual
clinical setting. And the associated factors inﬂuencing the poor
seizure outcome were also evaluated.
2. Methods
2.1. Patients
This was a retrospective, uncontrolled study conducted at the
Epilepsy Clinic of West China Hospital, a tertiary referral centre in
Chengdu, China. The epilepsy database (2010–2014) from this
Epilepsy Clinic was retrospectively reviewed. The Ethics Commit-
tee of the West China Hospital, Sichuan University approved the
study, and informed consent was obtained from each patient.
Patients who fulﬁlled the inclusion and had no exclusion criteria
were consecutively included in this study. The inclusion criteria
were as follows: (1) at least 16 years old and weight more than 40 kg;
(2) at least two well documented, unprovoked, clinically evaluated
and classiﬁed partial seizures (with or without secondary generali-
zation) within 12 months; (3) the ﬁrst AED was OXC prescribed at
the epilepsy clinic at the West China Hospital, which was continued
for at least 3 months; (4) no previous use of AEDs before attending
our clinic; and (5) follow up by at least for 12 months. Patients were
excluded from the study if they had less than one seizure per year
prior to treatment. Patients with suspected partial seizures who
have a clear IGE EEG were also excluded. Compliance with the
treatment regimen was monitored at the clinic, and patients with
persistent poor adherence to treatment, unrelated to efﬁcacy or
tolerability, seizures secondary to drug or alcohol abuse, or
documented psychogenic nonepileptic seizures were also excluded.
Follow-up was started at the introduction of OXC and was
ended at the discontinuation of treatment or closing date (July
2014), or death.
2.2. Treatment
For the majority of adult patients, OXC was prescribed initially
as 300 mg/day for two weeks, increasing to 600 mg/day in one
month. The OXC doses were adjusted as clinical circumstances
dictated, with particular attention paid to efﬁcacy and tolerability.
If the patient reported intolerable adverse effects with treatment,
an alternative was substituted. If the AED was well tolerated but
did not completely abolish the seizures, it was continually
increased to the doses or combination therapy was used, which
to a large degree was consistent with previous studies [16].
However, because of the pragmatic nature of this study, there were
no rigid rules concerning dose adjustments, and doses of OXC were
individualized. And moreover, based on the experience of clinic
practice and previous ﬁnding that Chinese patients receiving a
dose of more than 900 mg/day could be more likely to develop side
effects [17], and a higher risk of OXC-induced cutaneous adverse
reactions [18,19], the usual maintenance dose of OXC in our
patients was 600–900 mg/day and rarely more than 900 mg/day.
When possible, the patients were reviewed by the same clinician
every 8–12 weeks, or sooner if required. The follow-up clinical data
were collected in a structured record sheet and entered into a
computerized database.
2.3. Clinical information and demographic status
The following data regarding the clinical information and
demographic status were obtained from the medical records andinterview: age, gender, body weight, age at seizure onset, epilepsy
duration, seizure type, imaging (MRI/CT) ﬁndings, previous and
current AED use, time from onset of epilepsy to initiation of AED
treatment, OXC treatment (initiation date, daily dose, titration
regimen, date of discontinuation and reasons for discontinuation)
and the occurrence of any adverse events. Previous medical
history, including history of febrile seizures, cerebral infection and
brain injury, and family history of epilepsy were also obtained.
Duration of epilepsy was deﬁned as the period from the seizure
onset to the end of follow-up.
2.4. Statistical analysis
Data processing and analysis were performed with SPSS version
17.0 (SPSS Inc., Chicago, Illinois) for Windows. All outcome
variables were summarized using descriptive statistics. Continu-
ous variables were summarized as the mean  SD, and categorical
variables were summarized using counts and percentages. The
patients were divided into two groups: those who had been seizure-
free for at least 12 months were considered to have a good response
(good response group) and the remaining patients (were never
seizure-free for a complete year) were classiﬁed as having a poor
response (poor response group). Several continuous variables were
categorized. The current age was divided into 10-year groups. The
median age of epilepsy onset 21 years old was selected as the cut-off
point for onset age. The time from onset of epilepsy to the start of
treatment was divided into 1-year groups. The two-tailed chi-square
or Fisher’s exact tests were used for the comparison of categorical
data, whereas Student’s t test or the Mann–Whitney test were used
for the comparison of continuous data. Univariate binary logistic
regression was performed to determine the association between the
clinical and demographic variables and poor seizure outcome. A
model of multivariate logistic regression analysis was constructed to
determine the independent association with seizure outcome using a
backwards selection of covariates, and all results were expressed as
the odds ratios (ORs) and 95% conﬁdence intervals (CIs). All P-values
were two-sided, with P < 0.05 considered statistically signiﬁcant.
3. Results
3.1. Demographic and clinical characteristics of the included patients
A total of 102 eligible patients were included. The demographic
and clinical characteristics of the included patients are summa-
rized in Table 1. The mean age of all of the patients was 30.1  12.1
years. The mean age at seizure onset was 25.6  12.7 years. For the
brain MRI/CT results, 82 (80.4%) were normal and the other 20 (19.6%)
were abnormal. For seizure types, 28 (27.5%) patients had simple
partial seizures, 22 (21.6%) had complex partial seizures and the
remaining 52 (51.0%) showed partial seizures with secondary
generalization. The mean age at the initiation of OXC therapy was
27.9  12.0 years. The mean daily dose of OXC was 796.0  185.8 mg,
ranging from 600 to 1200 mg, and the time interval from onset of
epilepsy to the start of treatment averaged 2.3  3.3 years.
The seizure-free rates with successive regimens were shown in
Fig. 1 and Table S1. Twenty-seven (26.5%) of the 102 patients
achieved seizure-free with OXC 600 mg/day monotherapy. The
remaining 75 patients either had daily doses of OXC increasing to
900 mg (n = 59) or the addition of another AED (n = 16), with a
seizure-free rate of 33.9% (20) and 37.5% (6), respectively
(P = 0.788) (Table S2). For the 39 patients who did not become
seizure-free with OXC 900 mg/day, three were maintained on the
900 mg/day, and the remaining 36 patients either had daily doses
of OXC increasing to more than 900 mg (n = 10) or the addition of
another AED (n = 26), with two (20.0%) and eight (30.8%) patients
becoming seizure-free, respectively. Furthermore, one of four
Table 1
Demographic and clinical characteristics of the 102 subjects included in the present study.
Variable Good response (n = 64) Poor response (n = 38) Total (n = 102) P value
Gender 0.490
Male 43(67.2%) 28(73.9%) 71(69.6%)
Female 21(32.8%) 10(26.1%) 31(30.4%)
Age (years; mean  SD) 30.3  12.8 29.7  10.8 30.1  12.1 0.799
Weight (kg; mean  SD) 61.6  7.1 60.3  6.3 63.1  6.8 0.333
Onset age (years; mean  SD) 26.5  12.4 24.3  11.3 25.6  12.7 0.394
Age of therapy initiation (years; mean  SD) 28.2  12.8 27.47  10.7 27.9  12.0 0.764
Time from onset of epilepsy to start of treatment (years; mean  SD)* 1.7  2.7 3.4  3.8 2.3  3.3 0.021
Duration of epilepsy (years; mean  SD) 3.8  2.7 5.4  4.9 4.4  3.7 0.070
History
Febrile seizures 2(3.1%) 4(10.5%) 6(5.9%) 0.192
Cerebral infection 2(3.1%) 5(13.2%) 7(6.9%) 0.099
Cerebral trauma 1(1.6%) 4(10.5%) 5(4.9%) 0.063
First degree relative with epilepsy – – –
Seizure type 0.236
Simple partial 21(32.8%) 7(18.4%) 28(27.5%)
Complex partial 14(36.8%) 8(21.1%) 22(21.6%)
Secondary GTCS 29(45.3%) 23(60.5%) 52(51.0%)
MRI or CT results* 0.019
Normal 56(87.5%) 26(68.4%) 82(80.4%)
Abnormal 8(12.5%) 12(31.6%) 20(19.6%)
Duration of treatment (months; mean  SD) 24.5  7.9 22.2  7.2 23.6  7.7 0.144
Maximum dosage of OXC* (mg/day; mean  SD) 750.0  169.0 868.4  191.5 796.0  185.8 0.002
Adverse events 9(14.1%) 13(19.1%) 22(21.6%) 0.017
Note: The data are expressed as n (%), unless otherwise stated.
Abbreviations: SD, standard deviation; CT, computed tomography; MRI, magnetic resonance imaging; GTCS, generalized tonic–clonic seizure; OXC, oxcarbazepine.
The bold in the table indicates statistically signiﬁcant data.
Good response group was deﬁned as a seizure-free remission for at least 12 months.
Poor response group was deﬁned as no seizure-free remission for 12 months.
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additional AED became seizure-free.
Overall, a total of 21.6% (22) of the patients reported adverse
events, including dizziness (n = 6), headache (n = 3), drowsiness
(n = 4), nausea (n = 3), fatigue (n = 2), somnolence (n = 2), weight
gain (n = 1) and hyponatraemia (n = 1) (Table 2). All were mild to
moderate in nature and the majority were transient. No skin rash
was observed and no patients discontinued OXC as a result of the
adverse events. Moreover, there was no signiﬁcant difference in
the frequency of adverse events between the patients with OXC
monotherapy and those with a combination of OXC and other AEDs
(16.7% vs. 28.6%, P = 0.368) (Table 2).
3.2. Comparison of the variables in patients with good response and
poor response
The patients in good response Group (64) and in poor response
Group (38) did not differ signiﬁcantly for gender distribution, age,Fig. 1. Seizure-free rates with successive OXC monotherapy: 600 mg/day, 900 mg/
day and more than 900 mg/day, with seizure free rate 26.5%, 33.9% and 20.0%,
respectively.weight, age at seizure onset, duration of epilepsy, age at start of
therapy, duration of treatment, seizure types, history of febrile
seizures, cerebral infection and cerebral trauma. However,
compared to the patients with poor response, the patients with
good response had a lower proportion of abnormal MRI/CT ﬁndings
(12.5% vs. 31.6%, P = 0.023) and a signiﬁcantly less proportion of
patients presented adverse events (14.1% vs. 19.1%, P = 0.017), and
their mean daily dose of OXC was also signiﬁcantly lower than that
in poor response Group (750.0  169.0 mg vs. 868.4  191.5 mg,
P = 0.017). Moreover, the patients with poor response had a longer
time interval from the onset of epilepsy to the start of treatment
(3.4  3.8 vs. 1.7  2.7 years, P = 0.039) (Table 1).
3.3. Predictors related to poor response to treatment
The results of univariate binary regression showed that the
longer time interval from the onset of epilepsy to the start of
treatment (P = 0.041) and abnormal brain MRI/CT ﬁndings
(P = 0.023) were associated with a poor response (details in Table
S3). For the multivariable logistic regression model, only the time
interval from the onset of epilepsy to the start of treatment
(P = 0.020) was independently associated with the response.Table 2








Dizziness 3(5.0%) 3(7.1%) 6(5.9%)
Headache 2(3.3%) 1(2.4%) 3(2.9%)
Drowsiness 2(3.3%) 2(4.8%) 4(3.9%)
Nausea 1(1.7%) 2(4.8%) 3(2.9%)
Fatigue 1(1.7%) 1(2.4%) 2(2.0%)
Somnolence 1(1.7%) 1(2.4%) 2(2.0%)
Hyponatraemia 0 1a(2.4%) 1(1.0%)
Weight gain 0 1(2.4%) 1(1.0%)
Total 10(16.7%) 12(28.6%) 22(21.6%) 0.368
a The additional AED in the case with hyponatraemia was valproate.
Table 3
Multivariate logistic regression analyses for predictors of good outcome for newly
diagnosed partial epilepsy.






1b – – –
<2 and 1 0.929 0.615 0.395(0.118–1.319) 0.131
<3 and 2 1.721 0.735 0.179(0.042–0.756) 0.019
3 1.921 0.657 0.146(0.040–0.531) 0.003
Abbreviations: B, beta; SEB, standard error of beta; CI, conﬁdence interval.
a Age, gender, age at onset, seizure types, time from onset of epilepsy to starting
treatment, febrile seizures, cerebral infection and MRI/CT results. Only signiﬁcantly
associated factors are listed in this table.
b Reference category for the odds ratio.
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who had a time interval less than 1 year were more likely to
become seizure-free than those who had 2 and <3 years interval
(OR: 0.179, 95% CI: 0.042–0.756, P = 0.019) and 3 years interval
(OR: 0.146, 95% CI: 0.040–0.531, P = 0.003) (Table 3).
4. Discussion
In the present study conducted in an actual clinical setting in
west China, we found that 62.7% (64) of the 102 patients became
seizure-free for at least 12 months. Further, 49 of the 64 seizure-
free patients received OXC monotherapy; this conﬁrmed that OXC
is an effective ﬁrst-line therapy for adult patients with newly
diagnosed, previously untreated partial epilepsy [4].
As stated above, 49 (48.0%) of the patients became seizure free
with OXC monotherapy, whereas several previous clinical trials
evaluating the efﬁcacy and safety of OXC monotherapy versus
phenytoin [20], valproic acid [21], and CBZ [22], reported that the
proportion of seizure-free patients was 55–60% for OXC, and
several prospective open-label studies found a seizure-free rate of
61–63% for OXC monotherapy [23]. The slightly lower seizure-free
rate for OXC monotherapy in our study may be because, in our
study some patients who did not become seizure-free after OXC
600 mg/day were administered a second AED, rather than an
increased dose of OXC as the patients were given in the above
trials. However, a similar seizure-free rate was reported by Kwan
et al. for adult patients with new onset focal or generalized
seizures, of which approximately 50% of the patients become
seizure-free on their ﬁrst line AED [24].
For the maintenance doses of OXC, we found that compared to
patients with poor response, the seizure-free patients required
signiﬁcantly lower doses. This was consistent with the ﬁndings
from previous studies of patients who were treatment-responsive
and exhibited seizure control at lower doses of the prescribed AED
[16,25]. Furthermore, as expected, the average dose of OXC used in
our cohort was lower than that in previous trials, which averaged
approximately 1200 mg/day [4,7,8,26]. This may reﬂect the
different dosages required for the different patient populations
under evaluation. Another main ﬁnding of the present study was
that an additional 20 (19.6%) patients who did not become seizure-
free with OXC 600 mg/day monotherapy later became seizure-free
after doses of OXC increasing to 900 mg/day. Overall, 46% (47) of
our patients became seizure-free with a maintenance dose of no
more than 900 mg/day of OXC monotherapy, and a few became
seizure-free on OXC monotherapy at doses greater than 900 mg/
day. This suggests that OXC at low to moderate doses (900 mg/
day) are effective in treating Chinese adult patients with newly
diagnosed, previously untreated partial epilepsy.To the best of our knowledge, there is no published literature
regarding whether patients would beneﬁt more from continually
increasing the dose to 900 mg/day or a second AED added to
600 mg/day, when seizures are not well controlled after the initial
treatment of OXC 600 mg/day. In this retrospective study, no
statistically signiﬁcant differences were identiﬁed in the seizure-
free rates between the two regimens. Similarly, in a randomized
double-blind comparison of CBZ monotherapy (400 mg per day)
versus a combination of CBZ and valproate at reduced doses (200
and 300 mg per day, respectively) conducted in patients with
newly diagnosed epilepsy, no signiﬁcant differences were found
between the two treatments after a 1-year follow-up [27]. These
above ﬁndings indicate that there are no major advantages of
adjunctive therapy to monotherapy in these populations. More-
over, monotherapy for the management of epilepsy can minimize
the risk of toxicity, including teratogenicity, prevent drug
interactions, facilitate the assessment of drug response, and may
improve patient compliance, as well as patient well-being, with the
beneﬁt of achieving full seizure control [28,29].
Here, we found that OXC was well tolerated by our patients, and
all adverse events were mild to moderate in severity. No skin rash
was reported in our cohort. This was likely because that we
included patients taking OXC for at least 3 months, which may
have excluded patients who reported a rash and then substituted
another AED for OXC, and it may also be related to the low
initiation dosage of OXC and the slow titration in our patients.
Although there was a trend towards adverse reported among the
patients on combination therapy, the difference was not statisti-
cally signiﬁcant. This ﬁnding was similar to a randomized study, in
which monotherapy and polytherapy were compared in previously
untreated patients [27]. We found that patients who became
seizure-free reported a signiﬁcantly less proportion of adverse
events than those with a poor response. The main reason for this
difference may be that the majority of patients who were seizure-
free took signiﬁcantly lower doses that those who were not
seizure-free, and more patients who were seizure-free took
monotherapy than those who were not seizure-free.
It is important to identiﬁed patients whose seizures are likely to
be pharmacoresistant early on, which allows them to be referred
for epilepsy surgery at the most appropriate juncture [30].
Previously published studies showed a signiﬁcant effect for seizure
types, aetiology, age of onset, duration of epilepsy, number of
seizures before starting AED treatment, history of febrile convul-
sions and the response to the ﬁrst AED on prognosis [31–34]. In the
present study, we found that only longer time interval from onset
of epilepsy to the start of AED treatment signiﬁcantly indicated
poor response. It may be related to that patient with longer
duration of pre-treatment seizures usually had experienced more
seizures before the beginning of AED treatment. This ﬁnding was in
accordance with the view that a long history and high numbers of
pre-treatment seizures were thought to correlate with a poor
outcome, and early treatment of seizures, thereby minimizing the
number of subsequent seizures, was considered key to preventing
the emergence of drug-resistant epilepsy [35,36]. As previous
studies have shown, repeated seizures could produce neuronal loss
and mossy ﬁbre sprouting in the hippocampus, which in turn can
reinforce their production forming excitatory recurrent circuits,
and then resulting in drug resistance [37,38].
Because this was a single-centre study, it had good consistency
for the evaluation methodology, data collection, and data analysis.
However, our study also has several limitations. The primary
limitation is the small number of patients studied. We only
included patients continuing on OXC for a minimum of three
months and did not take retention on OXC treatment into
consideration. This may diminish the value of data on safety in
this study. In addition, no data was showed that the number of
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result in the weakness of the conclusion about the effect of delay
treatment. Because this was a retrospective study, some of the
epilepsy information may have been affected by recall bias.
However, this may be controlled for by performing population-
based studies or multicentre studies in the future. Despite these
limitations, we believe that our study has useful applications in
everyday clinical practice.
5. Conclusion
OXC at low to moderate dose is effective for the treatment of
Chinese adult patients with newly diagnosed, previously untreated
partial epilepsy, without introducing signiﬁcant adverse events. A
longer time interval from the onset of epilepsy to the start of
treatment signiﬁcantly predicts the poor seizure control, and
treating patients early may lead to improved outcomes.
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